CN101479385A - 用于乳腺癌治疗的hcap18/ll-37抑制剂 - Google Patents

用于乳腺癌治疗的hcap18/ll-37抑制剂 Download PDF

Info

Publication number
CN101479385A
CN101479385A CNA200780023565XA CN200780023565A CN101479385A CN 101479385 A CN101479385 A CN 101479385A CN A200780023565X A CNA200780023565X A CN A200780023565XA CN 200780023565 A CN200780023565 A CN 200780023565A CN 101479385 A CN101479385 A CN 101479385A
Authority
CN
China
Prior art keywords
cell
reagent
hcap18
cancer
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200780023565XA
Other languages
English (en)
Chinese (zh)
Inventor
莫娜·斯塔勒
京特·韦博
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipopeptide AB
Original Assignee
Lipopeptide AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipopeptide AB filed Critical Lipopeptide AB
Publication of CN101479385A publication Critical patent/CN101479385A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA200780023565XA 2006-05-04 2007-05-04 用于乳腺癌治疗的hcap18/ll-37抑制剂 Pending CN101479385A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0608797.7 2006-05-04
GBGB0608797.7A GB0608797D0 (en) 2006-05-04 2006-05-04 Novel agents and the use thereof

Publications (1)

Publication Number Publication Date
CN101479385A true CN101479385A (zh) 2009-07-08

Family

ID=36603894

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200780023565XA Pending CN101479385A (zh) 2006-05-04 2007-05-04 用于乳腺癌治疗的hcap18/ll-37抑制剂

Country Status (7)

Country Link
EP (1) EP2032699A2 (fr)
JP (1) JP2009535391A (fr)
CN (1) CN101479385A (fr)
AU (1) AU2007251359A1 (fr)
CA (1) CA2651064A1 (fr)
GB (1) GB0608797D0 (fr)
WO (1) WO2007132175A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2758967A1 (fr) 2009-04-16 2010-10-21 Forsyth Dental Infirmary For Children Nouveaux procedes de production d'un anticorps et compositions de celui-ci
CN101787368B (zh) * 2009-12-17 2013-03-27 湖南师范大学 抑制人Z38基因表达的siRNA及其在制备抗乳腺肿瘤药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1358888A1 (fr) * 2002-02-28 2003-11-05 Robert Bals L'Antibiotique peptidique humain LL-37/hCAP-18 est un inducteur de l'angiogénèse
JP2006514106A (ja) * 2002-12-19 2006-04-27 ヒルマン，イチャク 抗菌ペプチド阻害剤による疾患治療
EP1846444A2 (fr) * 2004-12-22 2007-10-24 Lipopeptide AB Nouveaux agents et leur utilisation

Also Published As

Publication number Publication date
CA2651064A1 (fr) 2007-11-22
GB0608797D0 (en) 2006-06-14
JP2009535391A (ja) 2009-10-01
AU2007251359A1 (en) 2007-11-22
WO2007132175A2 (fr) 2007-11-22
EP2032699A2 (fr) 2009-03-11
WO2007132175A3 (fr) 2008-05-22

Similar Documents

Publication Publication Date Title
Flemming et al. miRNA-and cytokine-associated extracellular vesicles mediate squamous cell carcinomas
US20210238249A1 (en) Modified mitochondria and use thereof
CN102099491A (zh) 调节血管生成的新靶标
US7741275B2 (en) Agents and use thereof
CN109913422A (zh) 一种包含肿瘤抗原识别受体的免疫细胞及其应用
CN102321158A (zh) 阻止细胞dna合成抑制细胞增殖的多肽及用途
ES2530091T3 (es) Composiciones peptídicas para el tratamiento del cáncer por la inhibición de la actividad del canal de calcio TRPV6
CN101479385A (zh) 用于乳腺癌治疗的hcap18/ll-37抑制剂
US20220162616A1 (en) Dual inhibition of plexin-b1 and plexin-b2
CN101478988A (zh) 联合治疗产品及其应用
Wang et al. Construction of human LRIG1-TAT fusions and TAT-mediated LRIG1 protein delivery
EP3384029B1 (fr) Facteur de croissance endothélial vasculaire hétérodimère et son utilisation
TWI606061B (zh) 用於治療乳癌的細胞穿透胜肽及其應用
US20100111913A1 (en) Method of enhancing migration of neural precursor cells
TWI634210B (zh) 抑制熱休克蛋白質表現之胜肽及包含其之組成物
US11136368B2 (en) Cancer treatment using CX26 blocking peptides
KR101491109B1 (ko) 면역내성암의 재발 및 암전이 예방 또는 치료용 조성물
DK2257299T3 (en) Modulation of SRPX2-mediated angiogenesis
JP2008271784A (ja) 新規薬剤デリバリー系
CN101821410A (zh) 印迹位点调节物兄弟(boris)的基因沉默
CN105483274B (zh) 与椎间盘退行性病变相关的基因标志物
KR20140045345A (ko) 질환을 치료하고, 진단하고, 모니터링하기 위한 조성물과 방법
KR20200122183A (ko) 암의 예방 또는 치료용 약학 조성물
CN115068614A (zh) 用于诊断、治疗和预防癌症的方法和组合物
KR20140086578A (ko) ＨＩＦ­１α ｓｉＲＮＡ 및 항산화제를 함유하는 재발암 또는 내성암의 치료 또는 예방용 약제학적 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication